Dermatofibrosarcoma protuberans and gastrointestinal stromal tumor as models for targeted therapy in soft tissue sarcomas

References

• Søreide K, Sandvik OM, Søreide JA, et al. Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies. Cancer Epidemiol. 2016 Feb;40:39–46. PubMed PMID: 26618334. DOI:10.1016/j.canep.2015.10.031
   PubMed Web of Science ®Google Scholar
• Blay JY, Bonvalot S, Casali P, et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol. 2005 Apr;16(4):566–578. PubMed PMID: 15781488. DOI:10.1093/annonc/mdi127
   PubMed Web of Science ®Google Scholar
• Joensuu H. Gastrointestinal stromal tumor (GIST). Ann Oncol. 2006 Sep;17(17 Suppl 10):x280–6. DOI:10.1093/annonc/mdl274. PubMed PMID: 17018739.
   PubMed Web of Science ®Google Scholar
• Miettinen M, Lasota J. Gastrointestinal stromal tumors–definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch. 2001 Jan;438(1):1–12. PubMed PMID: 11213830.
   PubMed Web of Science ®Google Scholar
• DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000 Jan;231(1):51–58. PubMed PMID: 10636102; PubMed Central PMCID: PMCPMC1420965.
   PubMed Web of Science ®Google Scholar
• Rutkowski P, Nowecki ZI, Michej W, et al. Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor. Ann Surg Oncol. 2007 Jul;14(7):2018–2027. PubMed PMID: 17473953. DOI:10.1245/s10434-007-9377-9
   PubMed Web of Science ®Google Scholar
• Nishida T, Goto O, Raut CP, et al. Diagnostic and treatment strategy for small gastrointestinal stromal tumors. Cancer. 2016 Oct 15;122(20):3110–3118. PubMed PMID: 27478963; PubMed Central PMCID: PMCPMC5096017. DOI:10.1002/cncr.30239
   PubMed Web of Science ®Google Scholar
• Miettinen M, Makhlouf H, Sobin LH, et al. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol. 2006 Apr;30(4):477–489. PubMed PMID: 16625094.
   PubMed Web of Science ®Google Scholar
• Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol. 2005 Jan;29(1):52–68. PubMed PMID: 15613856.
   PubMed Web of Science ®Google Scholar
• Rutkowski P, Wozniak A, Dębiec-Rychter M, et al. Clinical utility of the new American Joint Committee on Cancer staging system for gastrointestinal stromal tumors: current overall survival after primary tumor resection. Cancer. 2011 Nov 01;117(21):4916–4924. PubMed PMID: 21456019. DOI:10.1002/cncr.26079
   PubMed Web of Science ®Google Scholar
• Rossi S, Miceli R, Messerini L, et al. Natural history of imatinib-naive GISTs: a retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables. Am J Surg Pathol. 2011 Nov;35(11):1646–1656. PubMed PMID: 21997685. DOI:10.1097/PAS.0b013e31822d63a7
   PubMed Web of Science ®Google Scholar
• Ahmed I, Welch NT, Parsons SL. Gastrointestinal stromal tumours (GIST) – 17 years experience from Mid Trent Region (United Kingdom). Eur J Surg Oncol. 2008 Apr;34(4):445–449. DOI:10.1016/j.ejso.2007.01.006. PubMed PMID: 17320340.
   PubMed Web of Science ®Google Scholar
• Mendenhall WM, Zlotecki RA, Scarborough MT. Dermatofibrosarcoma protuberans. Cancer. 2004 Dec 01;101(11):2503–2508. doi:10.1002/cncr.20678. PubMed PMID: 15503305.
   PubMed Web of Science ®Google Scholar
• Lemm D, Mügge LO, Mentzel T, et al. Current treatment options in dermatofibrosarcoma protuberans. J Cancer Res Clin Oncol. 2009 May;135(5):653–665. PubMed PMID: 19205737. DOI:10.1007/s00432-009-0550-3
   PubMed Web of Science ®Google Scholar
• Chang CK, Jacobs IA. Salti GI. Outcomes of surgery for dermatofibrosarcoma protuberans. Eur J Surg Oncol. 2004 Apr;30(3):341–345. DOI:10.1016/j.ejso.2003.12.005. PubMed PMID: 15028319.
   PubMed Web of Science ®Google Scholar
• Fiore M, Miceli R, Mussi C, et al. Dermatofibrosarcoma protuberans treated at a single institution: a surgical disease with a high cure rate. J Clin Oncol. 2005 Oct 20;23(30):7669–7675. PubMed PMID: 16234529. DOI:10.1200/JCO.2005.02.5122
   PubMed Web of Science ®Google Scholar
• Harati K, Lange K, Goertz O, et al. A single-institutional review of 68 patients with dermatofibrosarcoma protuberans: wide re-excision after inadequate previous surgery results in a high rate of local control. World J Surg Oncol. 2017 Jan 05;15(1):5. PubMed PMID: 28056985; PubMed Central PMCID: PMCPMC5217543. DOI:10.1186/s12957-016-1075-2
   PubMed Web of Science ®Google Scholar
• Snow SN, Gordon EM, Larson PO, et al. Dermatofibrosarcoma protuberans: a report on 29 patients treated by Mohs micrographic surgery with long-term follow-up and review of the literature. Cancer. 2004 Jul 01;101(1):28–38. PubMed PMID: 15221986. DOI:10.1002/cncr.20316
   PubMed Web of Science ®Google Scholar
• Ballo MT, Zagars GK, Pisters P, et al. The role of radiation therapy in the management of dermatofibrosarcoma protuberans. Int J Radiat Oncol Biol Phys. 1998 Mar 01;40(4):823–827. PubMed PMID: 9531366.
   PubMed Web of Science ®Google Scholar
• Castle KO, Guadagnolo BA, Tsai CJ, et al. Dermatofibrosarcoma protuberans: long-term outcomes of 53 patients treated with conservative surgery and radiation therapy. Int J Radiat Oncol Biol Phys. 2013 Jul 01;86(3):585–590. PubMed PMID: 23628134. DOI:10.1016/j.ijrobp.2013.02.024
   PubMed Web of Science ®Google Scholar
• Daniels M, Lurkin I, Pauli R, et al. Spectrum of KIT/PDGFRA/BRAF mutations and phosphatidylinositol-3-kinase pathway gene alterations in gastrointestinal stromal tumors (GIST). Cancer Lett. 2011 Dec 15;312(1):43–54. PubMed PMID: 21906875. DOI:10.1016/j.canlet.2011.07.029
   PubMed Web of Science ®Google Scholar
• Wozniak A, Rutkowski P, Schoffski P, et al. Tumor genotype is an independent prognostic factor in primary gastrointestinal stromal tumors of gastric origin: a European multicenter analysis based on ConticaGIST. Clin Cancer Res. 2014 Dec 01;20(23):6105–6116. PubMed PMID: 25294914. DOI:10.1158/1078-0432.CCR-14-1677
   PubMed Web of Science ®Google Scholar
• Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998 Jan 23;279(5350):577–580. PubMed PMID: 9438854.
   PubMed Web of Science ®Google Scholar
• Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer. 2011 Nov 17;11(12):865–878. doi:10.1038/nrc3143. PubMed PMID: 22089421.
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003 Jan 31;299(5607):708–710. PubMed PMID: 12522257. DOI:10.1126/science.1079666
   PubMed Web of Science ®Google Scholar
• Pantaleo MA, Nannini M, Corless CL, et al. Quadruple wild-type (WT) GIST: defining the subset of GIST that lacks abnormalities of KIT, PDGFRA, SDH, or RAS signaling pathways. Cancer Med. 2015 Jan;4(1):101–103. PubMed PMID: 25165019; PubMed Central PMCID: PMCPMC4312123. DOI:10.1002/cam4.325
   PubMed Web of Science ®Google Scholar
• Rutkowski P, Przybyl J, Wozniak A, et al. Targeted therapy in gastrointestinal stromal tumors. In: Russo A., Rosell R., Rolfo C. editor. Targeted therapies for solid tumors. New York: Springer; 2015. p. 163–196.
   Google Scholar
• Croom KF, Perry CM. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours. Drugs. 2003;63(5): 513-22; discussion 523-4. PubMed PMID: 12600228.
   Web of Science ®Google Scholar
• Waller CF. Imatinib mesylate. Recent Results Cancer Res. 2010;184:3–20. PubMed PMID: 20072827. DOI:10.1007/978-3-642-01222-8_1
   PubMedGoogle Scholar
• Debiec-Rychter M, Sciot R, Le Cesne A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer. 2006 May;42(8):1093–1103. PubMed PMID: 16624552. DOI:10.1016/j.ejca.2006.01.030
   PubMed Web of Science ®Google Scholar
• Patrikidou A, Domont J, Chabaud S, et al. Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group. Eur J Cancer. 2016 Jan;52:173–180. PubMed PMID: 26687836. DOI:10.1016/j.ejca.2015.10.069
   PubMed Web of Science ®Google Scholar
• Lasota J, Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology. 2008 Sep;53(3):245–266. DOI:10.1111/j.1365-2559.2008.02977.x. PubMed PMID: 18312355.
   PubMed Web of Science ®Google Scholar
• Agaram NP, Laquaglia MP, Ustun B, et al. Molecular characterization of pediatric gastrointestinal stromal tumors. Clin Cancer Res. 2008 May 15;14(10):3204–3215. PubMed PMID: 18483389; PubMed Central PMCID: PMCPMC3805121. DOI:10.1158/1078-0432.CCR-07-1984
   PubMed Web of Science ®Google Scholar
• Simon MP, Pedeutour F, Sirvent N, et al. Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma. Nat Genet. 1997 Jan;15(1):95–98. PubMed PMID: 8988177. DOI:10.1038/ng0197-95
   PubMed Web of Science ®Google Scholar
• Sirvent N, Maire G, Pedeutour F. Genetics of dermatofibrosarcoma protuberans family of tumors: from ring chromosomes to tyrosine kinase inhibitor treatment. Genes Chromosomes Cancer. 2003 May;37(1):1–19. DOI:10.1002/gcc.10202. PubMed PMID: 12661001.
   PubMed Web of Science ®Google Scholar
• Greco A, Fusetti L, Villa R, et al. Transforming activity of the chimeric sequence formed by the fusion of collagen gene COL1A1 and the platelet derived growth factor b-chain gene in dermatofibrosarcoma protuberans. Oncogene. 1998 Sep 10;17(10):1313–1319. PubMed PMID: 9771975. DOI:10.1038/sj.onc.1202051
   PubMed Web of Science ®Google Scholar
• Greco A, Roccato E, Miranda C, et al. Growth-inhibitory effect of STI571 on cells transformed by the COL1A1/PDGFB rearrangement. Int J Cancer. 2001 May 01;92(3):354–360. PubMed PMID: 11291071.
   PubMed Web of Science ®Google Scholar
• Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002 Aug 15;347(7):472–480. PubMed PMID: 12181401. DOI:10.1056/NEJMoa020461
   PubMed Web of Science ®Google Scholar
• Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008 Feb 01;26(4):620–625. PubMed PMID: 18235121. DOI:10.1200/JCO.2007.13.4403
   PubMed Web of Science ®Google Scholar
• Group ESESNW. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014 Sep;25:Suppl 3: iii21-6. PubMed PMID: 25210085. DOI:10.1093/annonc/mdu255
   Web of Science ®Google Scholar
• von Mehren M. Management of gastrointestinal stromal tumors. Surg Clin North Am. 2016 Oct;96(5):1059–1075. DOI:10.1016/j.suc.2016.05.011. PubMed PMID: 27542643.
   PubMed Web of Science ®Google Scholar
• Casali PG, Zalcberg J, Le Cesne A, et al. Ten-year progression-free and overall survival in patients with unresectable or metastatic GI stromal tumors: long-term analysis of the european organisation for research and treatment of cancer, Italian sarcoma group, and Australasian gastrointestinal trials group intergroup phase III randomized trial on imatinib at two dose levels. J Clin Oncol. 2017 May 20;35(15):1713–1720. PubMed PMID: 28362562. DOI:10.1200/JCO.2016.71.0228
   PubMed Web of Science ®Google Scholar
• Rutkowski P, Andrzejuk J, Bylina E, et al. What are the current outcomes of advanced gastrointestinal stromal tumors: who are the long-term survivors treated initially with imatinib? Med Oncol. 2013 Dec;30(4):765. PubMed PMID: 24217870; PubMed Central PMCID: PMCPMC3840282.
   PubMed Web of Science ®Google Scholar
• Le Cesne A, Ray-Coquard I, Bui BN, et al. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncol. 2010 Oct;11(10):942–949. PubMed PMID: 20864406. DOI:10.1016/S1470-2045(10)70222-9
   PubMed Web of Science ®Google Scholar
• Reichardt P, Kang YK, Rutkowski P, et al. Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib. Cancer. 2015 May 01;121(9):1405–1413. PubMed PMID: 25641662; PubMed Central PMCID: PMCPMC4442000. DOI:10.1002/cncr.29220
   PubMed Web of Science ®Google Scholar
• Reichardt P, Demetri GD, Gelderblom H, et al. Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial. BMC Cancer. 2016 Jan 15;16:22. PubMed PMID: 26772734; PubMed Central PMCID: PMCPMC4714485. DOI:10.1186/s12885-016-2051-5
   PubMed Web of Science ®Google Scholar
• Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. Jama. 2012 Mar 28;307(12):1265–1272. PubMed PMID: 22453568. DOI:10.1001/jama.2012.347
   PubMed Web of Science ®Google Scholar
• Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006 Oct 14;368(9544):1329–1338. PubMed PMID: 17046465. DOI:10.1016/S0140-6736(06)69446-4
   PubMed Web of Science ®Google Scholar
• Demetri GD, Reichardt P, Kang YK, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013 Jan 26;381(9863):295–302. PubMed PMID: 23177515; PubMed Central PMCID: PMCPMC3819942. DOI:10.1016/S0140-6736(12)61857-1
   PubMed Web of Science ®Google Scholar
• McArthur GA, Demetri GD, Van Oosterom A, et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: imatinib Target Exploration Consortium Study B2225. J Clin Oncol. 2005 Feb 01;23(4):866–873. PubMed PMID: 15681532. DOI:10.1200/JCO.2005.07.088
   PubMed Web of Science ®Google Scholar
• Maki RG, Awan RA, Dixon RH, et al. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int J Cancer. 2002 Aug 20;100(6):623–626. PubMed PMID: 12209598. DOI:10.1002/ijc.10535
   PubMed Web of Science ®Google Scholar
• Rubin BP, Schuetze SM, Eary JF, et al. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol. 2002 Sep 01;20(17):3586–3591. PubMed PMID: 12202658. DOI:10.1200/JCO.2002.01.027
   PubMed Web of Science ®Google Scholar
• Rutkowski P, Van Glabbeke M, Rankin CJ, et al. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol. 2010 Apr 01;28(10):1772–1779. PubMed PMID: 20194851; PubMed Central PMCID: PMCPMC3040044. DOI:10.1200/JCO.2009.25.7899
   PubMed Web of Science ®Google Scholar
• Rutkowski P, Debiec-Rychter M, Nowecki Z, et al. Treatment of advanced dermatofibrosarcoma protuberans with imatinib mesylate with or without surgical resection. J Eur Acad Dermatol Venereol. 2011 Mar;25(3):264–270. PubMed PMID: 20569296. DOI:10.1111/j.1468-3083.2010.03774.x
   PubMed Web of Science ®Google Scholar
• Rutkowski P, Klimczak A, Ługowska I, et al. Long-term results of treatment of advanced dermatofibrosarcoma protuberans (DFSP) with imatinib mesylate - The impact of fibrosarcomatous transformation. Eur J Surg Oncol. 2017 Jun;43(6):1134–1141.
   Google Scholar
• Eilers G, Czaplinski JT, Mayeda M, et al. CDKN2A/p16 loss implicates CDK4 as a therapeutic target in imatinib-resistant dermatofibrosarcoma protuberans. Mol Cancer Ther. 2015 Jun;14(6):1346–1353. PubMed PMID: 25852058; PubMed Central PMCID: PMCPMC4458458. DOI:10.1158/1535-7163.MCT-14-0793
   PubMed Web of Science ®Google Scholar
• Ugurel S, Mentzel T, Utikal J, et al. Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-up. Clin Cancer Res. 2014 Jan 15;20(2):499–510. PubMed PMID: 24173542. DOI:10.1158/1078-0432.CCR-13-1411
   PubMed Web of Science ®Google Scholar
• Fields RC, Hameed M, Qin LX, et al. Dermatofibrosarcoma protuberans (DFSP): predictors of recurrence and the use of systemic therapy. Ann Surg Oncol. 2011 Feb;18(2):328–336. PubMed PMID: 20844969; PubMed Central PMCID: PMCPMC4310211. DOI:10.1245/s10434-010-1316-5
   PubMed Web of Science ®Google Scholar
• Kamar FG, Kairouz VF, Sabri AN. Dermatofibrosarcoma protuberans (DFSP) successfully treated with sorafenib: case report. Clin Sarcoma Res. 2013 Apr 04;3(1):5. DOI:10.1186/2045-3329-3-5. PubMed PMID: 23557478; PubMed Central PMCID: PMCPMC3637545.
   PubMedGoogle Scholar
• Fu Y, Kang H, Zhao H, et al. Sunitinib for patients with locally advanced or distantly metastatic dermatofibrosarcoma protuberans but resistant to imatinib. Int J Clin Exp Med. 2015;8(5):8288–8294. PubMed PMID: 26221412; PubMed Central PMCID: PMCPMC4509357.
   PubMed Web of Science ®Google Scholar
• Doyon C, Sideris L, Leblanc G, et al. Prolonged therapy with imatinib mesylate before surgery for advanced gastrointestinal stromal tumor results of a phase II trial. Int J Surg Oncol. 2012;2012:761576. PubMed PMID: 23316352; PubMed Central PMCID: PMCPMC3534224. DOI:10.1155/2012/761576
   PubMedGoogle Scholar
• Tielen R, Verhoef C, van Coevorden F, et al. Surgical treatment of locally advanced, non-metastatic, gastrointestinal stromal tumours after treatment with imatinib. Eur J Surg Oncol. 2013 Feb;39(2):150–155. PubMed PMID: 23084087. DOI:10.1016/j.ejso.2012.09.004
   PubMed Web of Science ®Google Scholar
• Wang D, Zhang Q, Blanke CD, et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132. Ann Surg Oncol. 2012 Apr;19(4):1074–1080. PubMed PMID: 22203182; PubMed Central PMCID: PMCPMC3800166. DOI:10.1245/s10434-011-2190-5
   PubMed Web of Science ®Google Scholar
• Rutkowski P, Gronchi A, Hohenberger P, et al. Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience. Ann Surg Oncol. 2013 Sep;20(9):2937–2943. PubMed PMID: 23760587.
   PubMed Web of Science ®Google Scholar
• Rutkowski P, Hompes D. Combined therapy of gastrointestinal stromal tumors. Surg Oncol Clin N Am. 2016 Oct;25(4):735–759. DOI:10.1016/j.soc.2016.05.006. PubMed PMID: 27591496.
   PubMed Web of Science ®Google Scholar
• Kérob D, Porcher R, Vérola O, et al. Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicenter phase II study on 25 patients. Clin Cancer Res. 2010 Jun 15;16(12):3288–3295. PubMed PMID: 20439456. DOI:10.1158/1078-0432.CCR-09-3401
   PubMed Web of Science ®Google Scholar
• Rutkowski P, Debiec-Rychter M. Current treatment options for dermatofibrosarcoma protuberans. PubMed PMID: 26027711 Expert Rev Anticancer Ther. 2015;158:901–909. 10.1586/14737140.2015.1052799
   PubMed Web of Science ®Google Scholar
• Joensuu H, Eriksson M, Sundby Hall K, et al. Adjuvant imatinib for high-risk GI stromal tumor: analysis of a randomized trial. J Clin Oncol. 2016 Jan 20;34(3):244–250. PubMed PMID: 26527782. DOI:10.1200/JCO.2015.62.9170
   PubMed Web of Science ®Google Scholar
• DeMatteo RP, Ballman KV, Antonescu CR, et al. Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial. Ann Surg. 2013 Sep;258(3):422–429. PubMed PMID: 23860199; PubMed Central PMCID: PMCPMC4041735. DOI:10.1097/SLA.0b013e3182a15eb7
   PubMed Web of Science ®Google Scholar